Table 3.
Neutralizing antibody titers generated by the DDMMPP regimen investigating plant‐produced (Group 3) and HEK293 cell‐derived (Group 4) HIV Env gp140
| ID50 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VSV‐G | MW965 | 6644 | CAP256 SU | ||||||||||
| Animal # | Group# | w0 | w14 | w30 | w0 | w14 | w30 | w0 | w14 | w30 | w0 | w14 | w30 |
| RB1 | 3 | <20 | <20 | <20 | <20 | 503 | 434 | <20 | 69 | 30 | <20 | 31 | 86 |
| RB2 | 3 | <20 | <20 | <20 | <20 | 1748 | 919 | 46 | 126 | 57 | 23 | <20 | <20 |
| RB3 | 3 | <20 | <20 | <20 | <20 | 335 | 115 | <20 | 54 | 31 | <20 | <20 | 38 |
| RB4 | 3 | <20 | <20 | <20 | <20 | 316 | 558 | 28 | 74 | 71 | <20 | <20 | 25 |
| RB5 | 3 | <20 | <20 | <20 | <20 | 233 | 349 | <20 | 88 | 23 | <20 | <20 | <20 |
| RB6 | 4 | <20 | <20 | <20 | <20 | 620 | 2147 | 21 | 68 | 107 | <20 | <20 | >540 |
| RB7 | 4 | <20 | <20 | <20 | <20 | 360 | 719 | 59 | 32 | 51 | 21 | <20 | 40 |
| RB8 | 4 | <20 | <20 | <20 | 29 | 183 | 1396 | <20 | <20 | 56 | <20 | <20 | <20 |
| RB9 | 4 | <20 | <20 | <20 | <20 | 80 | 42 | <20 | <20 | <20 | <20 | <20 | <20 |
| RB10 | 4 | <20 | <20 | <20 | <20 | 58 | 3116 | 25 | 29 | 172 | <20 | <20 | 33 |
| <20 | 20–99 | 100–499 | 500–999 | >1000 | |||||||||
Note: Week 0 comprises the pre‐bleed, Week 14 comprises the bleed after the second modified vaccinia ankara immunization, and Week 30 is the terminal bleed. The median titers are indicated in italics and bold where all animals produced neutralizing antibodies against the pseudovirus of interest. MW965 and 6644 represent Tier 1A and Tier 1B viruses, respectively, whereas CAP256 SU is the matched autologous virus.